Sarepta Therapeutics (SRPT) FCF Margin (2012 - 2026)
Sarepta Therapeutics (SRPT) recorded quarterly FCF Margin of 51.15% in Q1 2026, down 277.55% quarter-over-quarter from 28.81% in Q4 2025, and up 41916.0% on a YoY basis from N/an in Q1 2025.
Sarepta Therapeutics (SRPT) FCF Margin (2012 - 2026) Analysis & Trends
Sarepta Therapeutics' FCF Margin history runs 13 years deep, the most recent figure standing at 51.15% for Q1 2026.
- In Q1 2026, FCF Margin rose 41916.0% year-over-year to 51.15%; the TTM figure through Mar 2026 stood at 6.2% (up 4907.0% YoY), while the FY2025 annual figure was 13.99%, up 403.0% from the prior year.
- FCF Margin was 51.15% for Q1 2026 at Sarepta Therapeutics, down from 28.81% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 37.56% in Q2 2025 to a low of 629.86% in Q2 2023.
- Historically, FCF Margin has averaged 114.17% across 5 years, with a median of 35.93% in 2022.
- The sharpest annual moves came in 2023 and 2024: FCF Margin slumped 59392 bps in 2023, then soared 62594 bps in 2024.
- A 5-year view of FCF Margin shows it stood at 59.32% in 2022, then soared by 73 bps to 15.9% in 2023, then soared by 152 bps to 8.2% in 2024, then surged by 252 bps to 28.81% in 2025, then tumbled by 278 bps to 51.15% in 2026.
- The last three FCF Margin figures came in at 51.15% (Q1 2026), 28.81% (Q4 2025), and 9.39% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -3.98% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 43.35% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Sarepta Therapeutics | 1.84 Bn | 1.16 Bn | 291.52 Mn | -51.15% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -51.15% |
| Dec 31, 2025 | 28.81% |
| Sep 30, 2025 | -9.39% |
| Jun 30, 2025 | 37.56% |
| Mar 31, 2025 | -470.32% |
| Dec 31, 2024 | 8.20% |
| Sep 30, 2024 | -23.11% |
| Jun 30, 2024 | -3.92% |
| Mar 31, 2024 | -66.40% |
| Dec 31, 2023 | -15.90% |
| Sep 30, 2023 | -43.51% |
| Jun 30, 2023 | -629.86% |
| Mar 31, 2023 | -86.34% |
| Dec 31, 2022 | -59.32% |
| Sep 30, 2022 | -35.23% |
| Jun 30, 2022 | -35.93% |
| Mar 31, 2022 | -485.01% |
| Dec 31, 2021 | -28.16% |
| Sep 30, 2021 | -70.52% |
| Jun 30, 2021 | -81.11% |